Cassava CEO, ‘dazed and confused’, takes to biotech defense handbook by blaming short sellers for woes

The Cassava saga continues as chief Remi Barbier has come out, guns blazing, against accusations that the biotech may have deliberately misdirected investors on a recent Alzheimer’s disease readout.

Last month, a citizen petition filed with the FDA questioned the scientific integrity of the company's clinical trials for the Alzheimer’s drug simufilam and asked the agency to put them on hold.

The whistleblower petition detailed “grave concerns about the quality and integrity of the laboratory-based studies surrounding this drug candidate and supporting the claims for its efficacy.”